No sooner had Life Technologies Corp. (NASDAQ: LIFE ) announced its successful purchase of KDR Biotech last week, then out came Thermo Fisher Scientific (NYSE: TMO ) with a $13.6 billion bid to buy Life Technologies itself.
This morning, Life Technologies announced that it has signed a definitive agreement to sell itself to Thermo Fisher for $76 per share, or about $13.6 billion in total plus assumption of $2.2 billion in net debt. That assumption raises the deal value to $15.8 billion in total, easily trumping what was being reported last week as an estimated $11 billion bid for Life Technologies from private equity powerhouses Blackstone, Carlyle Group, and KKR.
The deal must be approved by shareholders and needs regulatory approval.
Thermo Fisher CEO Marc N. Casper was quoted in the company press release as saying that "Life Technologies enhances all three elements of our growth strategy: technological innovation, a unique customer value proposition and expansion in emerging markets." Life Technologies and Thermo Fisher say the deal will build on their "technological strengths to accelerate results for life sciences customers working in proteomics, genomics and cell biology."
Best Recreation Stocks To Buy For 2015: OncoMed Pharmaceuticals Inc (OMED)
OncoMed Pharmaceuticals, Inc. (OncoMed) incorporated on July 19, 2004, is a clinical development-stage biopharmaceutical company. The Company focuses on discovering and developing monoclonal antibody therapeutics targeting cancer stem cells (CSCs). It utilizes its technologies to identify, isolate and evaluate CSCs; identify and/or validate multiple potential targets and pathways critical to CSC self-renewal and differentiation; and develop targeted antibody and other protein-based therapeutics that are designed to modulate these CSC targets and inhibit the growth of CSCs. The Company's anti-cancer therapeutics include anti-DLL4 (demcizumab, OMP-21M18), Anti-DLL4/Anti-VEGF Bispecific, and Anti-Notch2/3 (OMP-59R5), Anti-Notch1 (OMP-52M51, Anti-Fzd7, Fzd8-Fc, RSPO-LGR.
Anti-DLL4 (demcizumab, OMP-21M18) is a humanized monoclonal antibody that inhibits Delta Like Ligand 4 (DLL4) in the Notch signaling pathway. The Company has completed a single-agent Phase Ia trial in advanced solid tumor patients. The Company focuses on conducting two Phase Ib combination trials of demcizumab. Anti-DLL4/anti-VEGF bispecific is a monoclonal antibody that targets and inhibits both DLL4 and vascular endothelial growth factor ( VEGF). VEGF is the target of Avastin. Anti-Notch2/3 (OMP-59R5) is a human monoclonal antibody that targets the Notch2 and Notch3 receptors.
Anti-Notch1 OMP-52M51 is a humanized monoclonal antibody targeted to the Notch1 receptor. Anti-Fzd7 OMP-18R5 is a human monoclonal antibody identified by screening against the Frizzled7 receptor (Fzd7) that binds a conserved epitope on five Frizzled receptors and inhibits Wnt signaling. OMP-18R5 is in a Phase I single-agent trial in advanced solid tumor patients. Fzd8-Fc OMP-54F28 is a fusion protein based on a truncated form of the Frizzled8 receptor ( Fzd8). RSPO-LGR ligands signal through the LGR receptor family.
The Company utilizes several robust technologies for the discovery and optimization of its antibody and protein-bas! ed therapeutics, including multiple proprietary technologies. Its antibody technologies include Mammalian Display Technology, Bispecific Antibody Technology, Hybridoma Technology. Mammalian Display Technology utilizes flow cytometry to isolate mammalian cells expressing antibodies on the cell surface with desired characteristics from large libraries of candidate antibodies. Bispecific Antibody Technology is used to generate its anti-DLL4/anti-VEGF antibody. Hybridoma Technology is used for isolating antibodies from mice, including multiplex single-cell screening techniques.
Advisors' Opinion:- [By Lauren Pollock]
Among the companies with shares expected to actively trade in Tuesday’s session are OncoMed Pharmaceuticals Inc.(OMED), Lexicon Pharmaceuticals Inc.(LXRX) and Krispy Kreme Doughnuts Inc.(KKD)
- [By WWW.DAILYFINANCE.COM] Stocks ended a mini-losing streak on Friday, led by upbeat news from Intel (INTC). The Dow Jones industrial average (^DJI) rose 41 points, after sliding more than 200 over the previous two days. The Nasdaq composite (^IXIC) gained 13 and the Standard & Poor's 500 index (^GPSC) added 6 points. Those modest gains did little to trim the loss for the week. The major averages posted their biggest weekly declines in more than two months. Intel is a component of all three big indexes, and it jumped 7 percent after raising its revenue guidance for the current quarter. The company sees stronger business demand for PCs than it previously expected. Intel shares are up 23 percent over the past six months. The Intel news had a ripple effect. Computer maker Hewlett-Packard (HPQ) rose more than 5 percent and Microsoft (MSFT) gained 1½ percent. Part of the increased demand Intel points to is tied to corporate buyers who need to replace their Windows XP machines, because Microsoft has stopped providing technical support for that platform. But Apple (AAPL) lost more than 1 percent. The stock is down since its 7-for-1 stock split took effect on Monday. There were two other big stories that had some legs beyond the companies directly involved. Open Table (OPEN) agreed to be acquired by Priceline (PCLN) for $2.6 billion. Open Table, which provides restaurant reservations, jumped 48 percent. Other online service providers rode the coattails of that deal. Yelp (YELP) gained 14 percent and Groupon (GRPN) gained 4 percent. In the retail arena, Express (EXPR) jumped 21 percent after a private equity firm took a 9.9 percent stake in the teen retailer and indicated it may make a buyout offer. That gave a boost to Aeropostale (ARO) and American Eagle (AEO), which both rose more than 2 percent. Abercrombie & Fitch (ANF) gained 1½. Elsewhere, International Game Technology (IGT) gained 10½ percent on a Reuters report that a bidding war could erupt for
Top 10 Life Sciences Stocks To Invest In Right Now: Adept Technology Inc.(ADEP)
Adept Technology, Inc., together with its subsidiaries, provides intelligent robotics systems and services for packaging, solar, medical, disk drive/electronics, machine tool automation, and automotive electronics markets. Its product range includes application software, integrated real-time vision and multi-axis motion controls, machine vision systems and software, autonomous navigation software and controls, industrial robots and grippers, autonomous service robots, intelligent automated guided vehicles (AGVs), and advanced vision-based flexible parts feeders. The company offers 4-axis Cobra family of robots, which are designed for assembly and material handling tasks; Adept Quattro parallel robots for high-speed packaging, assembly, and loading/unloading applications; Adept Viper 6-axis articulated robots for high-speed precision assembly; Modular Adept Python single axis robot mechanisms; and mobile robots, including autonomous service robots and intelligent AGVs. It a lso provides support services to customers, including spare parts for and/or remanufacture of robot mechanisms; information regarding the use of its automation equipment; ongoing support for installed systems; consulting services for applications; and training courses ranging from system operation and maintenance to programming for manufacturing engineers, who design and implement automation lines. The company markets its products through its direct sales force, as well as through systems integrators, sales representatives, distributors, and original equipment manufacturers primarily in the United States, Europe, and Asia. Adept Technology, Inc. was founded in 1983 and is headquartered in Pleasanton, California.
Advisors' Opinion:- [By GuruFocus]
George Soros (Trades, Portfolio) just reported his first quarter portfolio. He buys Citrix Systems Inc, Baker Hughes Inc, Comcast Corp, Spansion Inc, etc during the 3-months ended 03/31/2014, according to the most recent filings of his investment company, Soros Fund Management LLC. As of 03/31/2014, Soros Fund Management LLC owns 305 stocks with a total value of $10.1 billion. These are the details of the buys and sells.New Purchases: BHI, CODE, CTRP, CLI, AVB, COMM, CNQ, AGO, AUY, ATML, ASH, BXMT, CSTM, AEM, CMA, ARE, CHKP, AUQ, BEAV, CX, ADSK, AALCP, BLK, AIG, BIIB, ADEP, AMRI, ARWR, ATHX, BALT, BCRX, BEAT, CFX, CLFD, CUR, CODE,Added Positions: CTXS, CMCSA, CNP, ALTR, BRCD, CBS, CRM, CHTR, CCJ, CIEN, BIDU, ALLE, ABT, CDNS, ACT,Reduced Positions: AAPL, CCI, AMT, ABBV, AAL, BITA, AL, ANGI, ARIA, CBST, BA, BIRT, EXAR,Sold Out: C, BAC, CRI, AMZN, AGN, CF, BRCM, COTY, BMY, AMCX, CAR, A, ADBE, AFL,For the details of George Soros (Trades, Portfolio)'s stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=George+SorosThis is the sector weightings of his portfolio:Technology18.9%Energy14%Healthcare8.3%Consumer Defensive8.2%Communication Services8.1%Consumer Cyclical5.4%Industrials5.1%Basic Materials4.9%Financial Services2.5%Real Estate1.9%Utilities0.5%These are the top 5 holdings of George Soros (Trades, Portfolio)1. Teva Pharmaceutical Industries Ltd (TEVA) - 10,310,041 shares, 5.4% of the total portfolio. Shares added by 10.67%2. Herbalife Ltd (HLF) - 4,901,337 shares, 2.8% of the total portfolio. Shares added by 52.9%3. EQT Corp (EQT) - 2,573,814 shares, 2.5% of the total portfolio. Shares added by 3.27%4. Adecoagro SA (AGRO) - 25,915,076 shares, 2.1% of the total portfolio.5. Halliburton Co (HAL) - 3,596,353 shares, 2.1% of the total portfolio. Shares reduced by 20.73%New Purchase: Baker Hughes Inc (BHI)George Soros (Trades, Portfolio) initiated holdings in Baker Hughes Inc. His purchase prices were between $51.82 and $65.27, with an estimated
- [By Jake L'Ecuyer]
Leading and Lagging Sectors
Technology stocks gained Thursday, with Infinera (NASDAQ: INFN) leading advancers. Meanwhile, gainers in the sector included Envivio (NASDAQ: ENVI), with shares up 2.8 percent, and Adept Technology (NASDAQ: ADEP), with shares up 4.3 percent.
Top 10 Life Sciences Stocks To Invest In Right Now: Sony Corp Ord(SNE)
Sony Corporation designs, develops, manufactures, and sells electronic equipment, instruments, and devices for consumer, professional, and industrial markets worldwide. The company offers consumer products and devices, including televisions, video cameras, compact digital cameras and interchangeable single-lens cameras, Blu-ray Disc players/recorders, DVD-video players/recorders, home theaters and audio systems, and portable audio and car audio products. It also provides charged coupled devices, complementary metal-oxide semiconductor image sensors, system LSIs, small- and medium-sized LCD panels, and other semiconductors; and components, such as batteries, optical disk drives, chemical products, audio/video/data recording media, storage media, and optical pickups. In addition, the company develops, produces, markets, and distributes games, such as PlayStation3, PlayStation Portable, and PlayStation 2 hardware and related software; and PCs and flash memory digital audio pl ayers, as well as manufactures broadcast- and professional-use products, Blu-ray discs, DVDs, and CD discs. Further, it produces and distributes motion pictures and television programs, and home entertainment; creates and distributes digital content; operates television networks and studio facilities; and develops entertainment products, services, and technologies. Additionally, the company engages in the music publishing business, as well as provision of various financial services, including insurance, savings products, loans, and credit financing services; and a network service business and an advertising agency business. It also involves in research, development, design, production, marketing, sales, distribution, and servicing mobile phones, accessories, services, and applications. The company was formerly known as Tokyo Tsushin Kogyo Kabushiki Kaisha and changed its name to Sony Corporation in 1958. Sony Corporation was founded in 1946 and is based in Tokyo, Japan.
Advisors' Opinion:- [By Paul Ausick]
Sony Corp. (NYSE: SNE) is scheduled to launch its PlayStation 4 at roughly the same time and the Japanese company�� PlayStation Plus free online gaming service, which has been a big hit among gamers, forced Microsoft to unveil its own sort-of-free Xbox Live Gold service. Under Microsoft�� plan gamers get a rotating offering of two free games a month along with their subscription.
Top 10 Life Sciences Stocks To Invest In Right Now: Ellie Mae Inc (ELLI)
Ellie Mae, Inc., incorporated October 14, 2007, is a provider of on-demand automation solutions for the mortgage industry. The Company offers an end-to-end solution, delivered using a Software-as-a-Service model that serves as the core operating system for mortgage originators and spans customer relationship management, loan origination and business management. It also hosts the Ellie Mae Network that allows Encompass users to electronically conduct business transactions with the lenders and settlement service providers they work with to process and fund loans. The Company's offerings include range of Encompass services and the DataTrac mortgage management software system. On August 15, 2011, it completed the acquisition of Del Mar Datatrac,Inc. (DMD).
Using the Company�� network technology, it has helped connect a fragmented world of mortgage bankers, mortgage brokers, community banks, credit unions, lenders, investors and service providers, all of which are integral to the origination and funding of residential mortgages. Its Encompass360 solutions include Encompass Product & Pricing Service; Ellie Mae Total Quality Loan Program; Encompass Compliance Service; Encompass Appraisal Service; Encompass CenterWise; Encompass Commissions; Encompass TPO WebCenter and Encompass Docs Solution.
Ellie Mae�� Total Quality Loan program helps in identifying compliance, income and fraud issues early in the origination process; help protect business from loan buy-backs, and fortify workflow and uncover and correct possible issues before you close the loan.Encompass Appraisal Service, integrated inside Encompass360, is that solution helps in completing order right from the loan file in Encompass360; import complete appraisal reports directly into eFolder, and customize appraisal workflow by type of loan and control, which its users can order appraisals. Its Encompass CenterWise wraps two essential Web and electronic document solutions into one unified package. Encompass Commissions is a ! commission management solution integrated inside Encompass360 that automates the calculation, reconciliation and communication of variable pay across your organization. Hosted Encompass360 Banker Edition users can connect directly with third-party originators (TPOs) without leaving Encompass360, and have them connect back in a secure, synchronized, and easy-to-use Web-based environment. Encompass Docs Solution provides a single, integrated application incorporating both initial disclosures and closing documents.
Advisors' Opinion:- [By Roberto Pedone]
Ellie Mae (ELLI), an electronic mortgage origination network in the U.S, closed up 16% at $28 in Friday's trading session.
Friday's Volume: 2.17 million
Three-Month Average Volume: 468,756
Volume % Change: 372%Shares of ELLI skyrocketed higher on Friday after the company reported a profit and met Wall Street's expectations and beat the revenue expectation.
From a technical perspective, ELLI soared higher here right above both its 50-day moving average of $23.64 and its 200-day moving average of $23.71 with heavy upside volume. This move sent shares of ELLI into breakout territory, since the stock took out some key overhead resistance levels at $25.39 to $25.75 and then above more resistance at $26.34. This move also pushed shares of ELLI into new 52-week high territory, which is bullish technical price action. Shares of ELLI are now starting to move within range of triggering another major breakout trade. That trade will hit if ELLI manages to take out Friday's high of $28.100 and then once it clears its three-year high at $30.59 with high volume.
Traders should now look for long-biased trades in ELLI as long as it's trending above those breakout levels of $26.34 to $25.75 and then once it sustains a move or close above those breakout levels with volume that's near or above 468,756 shares. If that breakout triggers soon, then ELLI will set up to enter new 52-week- and three-year-high territory, which is bullish technical price action. Some possible upside targets off that breakout are $35 to $40.
- [By Lauren Pollock]
Among the companies with shares expected to actively trade in Friday’s session are WellCare Health Plans Inc.(WCG), First Solar Inc.(FSLR) and Ellie Mae Inc.(ELLI)
- [By Simon Erickson]
Rule Breakers analyst Simon Erickson believes Ellie Mae (NYSE: ELLI ) , an innovator in the mortgage industry, could be in a perfect place to capitalize on the situation. In the video below, he presents three reasons he thinks the stock is a buy today.
- [By SA Pro Top Ideas]
Stock Movers and Great Calls
Saidal Mohmand argued Wednesday that Tellabs (TLAB) was a strong assets play on the verge of a turnaround. The stock is +5.9% since. Read article » On June 13, Stephen Lin said that Ellie Mae's (ELLI) dominant position could mean 45% upside. Shares are +30.7% since. Read article »
Alpha-Rich long and short ideas regularly move stocks and identify stocks that are about to move. Some notable recent calls subscribers had early access to:To Come Today
Don't forget to check your SA Pro dashboard later today for the latest Alpha-Rich ideas, including a REIT with strong management and many catalysts. Any thoughts to share on the latest Alpha-Rich ideas? Leave a comment here. Have a great weekend.
SA Pro Editors
…............
The SA Pro team is Eli Hoffmann (Editor in Chief), Rachael Granby (Editorial Product Manager), Daniel Shvartsman, Samir Patel, Michael McDonald, and Jeffrey Fischer (Senior Pro Editors). You can reach us at pro-editors@seekingalpha.com.
Top 10 Life Sciences Stocks To Invest In Right Now: Akamai Technologies Inc.(AKAM)
Akamai Technologies, Inc. provides content delivery and cloud infrastructure services for accelerating and improving applications over the Internet in the United States and internationally. The company offers application and cloud performance solutions to enhance the operation of the applications used by enterprises to connect with their employees, suppliers, and customers. Its solutions include Web Application Accelerator, which enables enterprises to run various applications; and IP Application Accelerator that is designed to optimize the performance, availability, and real-time sensitivity associated with IP-enabled applications delivered over Internet-related protocols. The company also provides video and software solutions that are designed to enable enterprises to execute their large file management and distribution strategies, which include media delivery solution to entertainment industry; and electronic software delivery solution that handles the distribution of s oftware for its customers. In addition, it offers Website optimization services for accelerating business-to-consumer Websites that integrate collaborative content and applications into their online architecture; security and protection solutions that address the Internet security requirements; and network operator solutions, which provide custom solutions to commercial and government customers. Further, the company provides mobile content adaptation solution; and advertising decision solutions that enable advertisers, agencies, publishers, and networks to buy and sell advertising, as well as network data feeds, Website analytics, and business performance management services. It markets and sells its services and solutions through direct sales and services organization; and through active channel partners. Akamai Technologies, Inc. was founded in 1998 and is headquartered in Cambridge, Massachusetts.
Advisors' Opinion:- [By WALLSTCHEATSHEET]
Akamai Technologies provides new cloud services and computing technology that is being adopted at increasing rates by companies and consumers worldwide. The stock has been quiet in recent times but is now trading at the top-end of a multi-year range. Over the last four quarters, Akamai Technologies has seen increasing earnings and revenue figures that have kept investors excited. Relative to its peers and sector, Akamai Technologies has been a year-to-date performance leader. Look for Akamai Technologies to OUTPERFORM.
- [By Lauren Pollock]
Akamai Technologies Inc.(AKAM) agreed to buy Prolexic Technologies Inc. for about $370 million in cash, expanding its cybersecurity offerings. Prolexic, a provider of cloud-based security services for protecting data centers and Internet Protocol applications from distributed denial of service attacks, will be added to Akamai’s services for defending Web sites and Web applications.
- [By Sally Jones]
Today�� theme is the letter ��,��representing amazing gains on advanced technology stocks in companies beginning with the letter A. In the first half of 2013, billionaire investors were trading these ��-list��technology stocks from the S&P500, including Amphenol Corporation (APH), Akamai Technologies Inc. (AKAM) and Analog Devices Inc. (ADI). These companies were screened for their billionaire stakeholders, high gains, recent insider trading and yield.
Top 10 Life Sciences Stocks To Invest In Right Now: Jinzanghuang Tibet Pharmaceuticals Inc (JZHG)
Jinzanghuang Tibet Pharmaceuticals, Inc. distributes Tibetan pharmaceutical and nutraceutical products in the People�� Republic of China (PRC) through Leling Jinzanghuang Biotech Co., Ltd. (Leling JZH). The Company, through its wholly owned subsidiary, Tibet Medicine, Inc., owns 100% of Beijing Taibodekang Consulting Co., Ltd. (Beijing Taibodekang), a wholly foreign owned entity. Beijing Taibodekang had entered into four agreements with Leling Jinzanghuang Biotech Co., Ltd. (Leling Jinzanghuang) and with the equity owners in Leling Jinzanghuang. Collectively, the agreements provide Beijing Taibodekang exclusive control over the business of Leling Jinzanghuang. Leling Jinzanghuang engages in the distribution of the pharmaceutical and nutraceutical products that Tibetans have used for centuries to treat diseases and facilitate health. The distributed products are classified by Leling Jinzanghuang in three major categories: pharmaceuticals, therapeutic supplements, and dietary supplements.
The 13 Tibetan health products that Leling Jinzanghuang distributes are among those Tibetan medicines made with modern drug manufacturing techniques. The manufacturing equipment and techniques used by its supplier are certified under China�� national standards of Good Manufacturing Practice (GMP), and are in compliance with applicable regulations of the Chinese Food and Drug Administration (SFDA), which regulates both the pharmaceutical and the nutraceutical industries in China.
Ying Huang Tablet
Ying Huang Tablet is one the two pharmaceutical products marketed by Leling Jinzanghuang that been approved by SFDA. The effective ingredients in the Ying Huang Tablet are extracts from the honeysuckle and the Huangqin herb. It can be used to treat upper respiratory infections including pharyngitis, encephalitis and conjunctivitis. It can also be used to reduce inflammation and relieve pain.
San Qi Capsules
San Qi Capsules is a dietary supplements certified! by SFDA. San Qi Capsules lower blood lipid and cholesterol levels. Thus they can be used as a precautionary therapy to prevent cardiovascular diseases, including coronary heart disease, heart angina and stroke. In addition, the San Qi Capsules enhance immune system functions, which may help in the prevention of cancer.
Foshou Capsules
Foshou Capsules is a Tibetan nutraceutical. The effective ingredients, Xue Yu, Dongchong Xiacao, Fozhang, and Ginseng, are extracts of several plants and animals that are native to the Tibet Plateau.
Bai He Capsules
Bai He Capsules is a Tibetan dietary supplement. The effective ingredients consist of Baihe, Fozhang Ginseng and Himalayan purple jasmine. The Bai He Capsules are used to treat male erectile dysfunction and other sexual dysfunction problems.
The Company competes with Jingqiu Tibetan Medicine, Jinhe Tibetan Medicine and Tibetan Pharmaceutical Factory, Tibet Cheezheng Tibetan Medicine and Niemula Tibet Medicine.
Advisors' Opinion:- [By Peter Graham]
Small cap medical technology stock Sanomedics International Holdings (OTCMKTS: SIMH) recently completed financing and an acquisition while JinZangHuang Tibet Pharmaceuticals, Inc (OTCMKTS: JZHG) surged 48.28% on Friday. However, that�� only part of the story as one of these stocks has been the subject of paid promotions while the other has no new news for investors. So are either of these small cap stocks the cure for any portfolio pains you may be suffering from? Here is a quick reality check:
Top 10 Life Sciences Stocks To Invest In Right Now: Rutter Inc (RUT)
Rutter Inc. (Rutter) focuses on providing technologies and manufacturing solutions. The Company supplies technologies to improve efficiency and safety in the marine, defense, transportation, oil and gas sectors. The Company produces and globally markets enhanced radar systems, including oil spill detection, ice navigator, small target detection and wave-monitoring systems. The Company also offers a full range of outsource manufacturing services including: product engineering and design; materials management; manufacturing; sub-assembly; systems integration; project management; testing; logistics and documentation and provides full cycle customer support for all Company products and selected third party components/products that it manufactures under contract. Rutter�� sigma S6 radar signal processing products are designed to enable end users to detect and track objects which would not be visible with conventional radar equipment only. Advisors' Opinion:- [By Victor Reklaitis]
Meanwhile, the Russell 2000 index (RUT) , a gauge of small-cap stocks, was up 20.88 points, or 1.9%, at 1,099.97. Some eyebrows were raised Wednesday when the Russell diverged, ending lower as the S&P 500 gained ground. The Russell, however, outpaced the S&P 500 on Friday, though it still slightly underperformed for the week, gaining 0.4%.
